Loading clinical trials...
Loading clinical trials...
Multicenter Phase I/II Clinical Trial of Recombinant Human Endostatin Continued Pumping Into Vein Combining With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer
Conditions
Interventions
Recombinant human endostatin
Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles
+3 more
Locations
1
China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Start Date
November 1, 2012
Primary Completion Date
June 1, 2015
Completion Date
June 1, 2015
Last Updated
July 14, 2017
Lead Sponsor
Zhejiang Cancer Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions